Exenatide Doesn't Up Cardiovascular Risk in T2DM

This article originally appeared here.
Share this content:
Exenatide Doesn't Up Cardiovascular Risk in T2DM
Exenatide Doesn't Up Cardiovascular Risk in T2DM

THURSDAY, Sept. 14, 2017 (HealthDay News) -- For patients with type 2 diabetes, the incidence of major cardiovascular events is similar for those receiving exenatide or placebo, according to a study published online Sept. 14 in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the European Association for the Study of Diabetes, held from Sept. 11 to 15 in Lisbon, Portugal.

Rury R. Holman, F.Med.Sci., from the University of Oxford in the United Kingdom, and colleagues randomized 14,752 patients (73.1 percent with previous cardiovascular disease) with type 2 diabetes to receive extended-release exenatide or placebo once weekly.

The researchers found that 11.4 percent of patients in the exenatide group and 12.2 percent in the placebo group had a primary composite event (hazard ratio, 0.91; 95 percent confidence interval, 0.83 to 1.00); in the intention-to-treat analysis, exenatide was non-inferior to placebo with respect to safety (P < 0.001), but was not superior with respect to efficacy (P = 0.06). There was no significant difference between the groups in the rates of death from cardiovascular causes, fatal or nonfatal myocardial infarction, fatal or nonfatal stroke, heart failure hospitalization, or acute coronary syndrome hospitalization.

"Once-weekly administration of extended-release exenatide in patients with type 2 diabetes at a wide range of cardiovascular risk appeared not to cause an increase in their overall cardiovascular risk," the authors write.

The study was funded by Amylin Pharmaceuticals, a wholly owned subsidiary of AstraZeneca, the manufacturer of exenatide.

Abstract
Full Text
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »